Lineage Cell Therapeutics
LCTX
LCTX
80 hedge funds and large institutions have $152M invested in Lineage Cell Therapeutics in 2016 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 27 increasing their positions, 10 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
0.61% more ownership
Funds ownership: 42.79% → 43.4% (+0.61%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
68% less call options, than puts
Call options by funds: $103K | Put options by funds: $318K
Holders
80
Holding in Top 10
1
Calls
$103K
Puts
$318K
Top Buyers
| 1 | +$1.07M | |
| 2 | +$799K | |
| 3 | +$330K | |
| 4 |
State Street
Boston,
Massachusetts
|
+$274K |
| 5 |
D.E. Shaw & Co
New York
|
+$254K |
Top Sellers
| 1 | -$204K | |
| 2 | -$153K | |
| 3 | -$93.4K | |
| 4 |
ST
Spot Trading
Chicago,
Illinois
|
-$73.8K |
| 5 |
Wolverine Trading
Chicago,
Illinois
|
-$58K |